NORDIC BIOTECH K/S: Financial statements 2022
CVR: 26290724
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
NORDIC BIOTECH K/S (CVR 26290724) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -44,572,000 compared with DKK -6,387,000 the year before. Equity in the 2022 report amounted to DKK 34,150,000. The solvency ratio was 99.8%.
- Profit/Loss
- DKK -44,572,000
- Equity
- DKK 34,150,000
- Total Assets
- DKK 34,208,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | -44.6M | 34.2M | 0 |
| 2021 | - | - | -6.4M | 78.7M | 0 |
| 2020 | - | - | -1.4M | 85.1M | 0 |
| 2019 | - | - | 13M | 86.5M | 0 |
| 2018 | - | - | -464.7M | 73.5M | - |
Official annual report
Keep an eye on NORDIC BIOTECH K/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
NORDIC BIOTECH K/S has published its annual report for 2021. The net result was DKK -6,387,000.
About NORDIC BIOTECH K/S
NORDIC BIOTECH K/S was a Danish company of the type Kommanditselskab based in Hellerup, founded in 2001. The company has been dissolved on 22 December 2025. The company was registered under the industry Anden finansiel formidling i.a.n.. The company has 0 employees (2011). In 2024, the company reported a gross profit of DKK -157,000 and a net result of DKK 101,458,000 compared with DKK 1,254,000 the year before. Equity in the 2024 report amounted to DKK 127,032,000.
